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revention and Treatment of Microvascular
bstruction-Related Myocardial Injury
nd Coronary No-Reflow Following
ercutaneous Coronary Intervention
Systematic Approach
onen Jaffe, MD,* Alexander Dick, MD,† Bradley H. Strauss, MD, PHD†
aifa, Israel; and Toronto, Ontario, Canada
icrovascular obstruction (MVO) commonly occurs following percutaneous coronary interventions (PCI),
ay lead to myocardial injury, and is an independent predictor of adverse outcome. Severe MVO may man-
fest angiographically as reduced ﬂow in the patent upstream epicardial arteries, a situation that is termed
no-reﬂow.” Microvascular obstruction can be broadly categorized according to the duration of myocardial
schemia preceding PCI. In “interventional MVO” (e.g., elective PCI), obstruction typically involves myocar-
ium that was not exposed to acute ischemia before PCI. Conversely “reperfusion MVO” (e.g., primary PCI
or acute myocardial infarction) occurs within a myocardial territory that was ischemic before the coronary
ntervention. Interventional and reperfusion MVO have distinct pathophysiological mechanisms and may
equire individualized therapeutic approaches. Interventional MVO is triggered predominantly by down-
tream embolization of atherosclerotic material from the epicardial vessel wall into the distal microvascula-
ure. Reperfusion MVO results from both distal embolization and ischemia-reperfusion injury within the sub-
ended ischemic tissue. Management of MVO and no-reﬂow may be targeted at different levels: the
picardial artery, microvasculature, and tissue. The aim of the present report is to advocate a systematic
pproach to prevention and treatment of MVO in different clinical settings. Randomized clinical trials have
tudied strategies for prevention of MVO and no-reﬂow; however, the efﬁcacy of measures for reversing
VO once no-reﬂow has been demonstrated angiographically is unclear. New approaches for prevention
nd treatment of MVO will require a better understanding of intracellular cardioprotective pathways such as
he blockade of the mitochondrial permeability transition pore. (J Am Coll Cardiol Intv 2010;3:695–704)
2010 by the American College of Cardiology Foundation“
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whe concept of microvascular obstruction (MVO)
ollowing percutaneous coronary interventions (PCI)
efers to myocardial tissue hypoperfusion in the pres-
nce of patent epicardial coronary circulation. Severe
VO may lead to overt reduction in flow in the
atent upstream epicardial arteries, which is termed
rom the *Lady Davis Medical Center, Department of Cardiology,
aifa, Israel; and the †Schulich Heart Programme, Sunnybrook Health
ciences Centre, University of Toronto, Toronto, Ontario, Canada.m
anuscript received February 21, 2010; revised manuscript received May
0, 2010, accepted May 12, 2010.no-reflow.” No-reflow is associated with adverse
linical outcomes and is caused by MVO (200
m), which may result from multiple pathophysio-
ogical mechanisms. Diagnostic modalities that have
role in evaluating microvascular perfusion include
T-segment resolution on the electrocardiogram,
ngiographic measures of coronary flow and tissue
erfusion, contrast echocardiography, magnetic reso-
ance imaging, computed tomography, and intra-
oronary measurement of flow velocity by Doppler
ire (1). Tissue hypoperfusion following PCI leads to
yocardial ischemia, which may result in elevation of
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696erum markers of cardiac injury. We have recently reviewed the
athophysiology of 2 related clinical entities that are charac-
erized by MVO but differ in several fundamental ways (1). In
VO following PCI outside of the acute infarct setting, which
e have termed “interventional MVO,” the myocardial tissue
ubtended by the treated coronary artery is not typically
ubjected to acute ischemia before the intervention, and the
rocedure-induced MVO is caused primarily by distal micro-
mbolization. In contrast, “reperfusion MVO,” occurring in the
cute infarct setting, results from complex pathophysiological
echanisms that include ischemic and reperfusion injury as
ell as distal microembolization of plaque and thrombus. In
his review, we discuss the therapeutic options for both
revention and treatment of MVO and no-reflow in these 2
ettings.
revention and Treatment of MVO and No-Reflow:
xperimental and Clinical Experience
echanisms of MVO include mechanical plugging second-
ary to distal embolization from
the epicardial coronary arteries,
external compression by edema-
tous tissue, in situ thrombosis,
vasospasm, activation of inflam-
matory cascades with leukocyte
stasis and extravasation, and
reperfusion injury (2). Interven-
tions for optimizing tissue per-
fusion following PCI may be
targeted at the epicardial coro-
nary artery, the microvascula-
ture, and the subtended myo-
cardial tissue (Figs. 1 and 2).
ultiple therapies for MVO and no-reflow have been
ested in animals and to a lesser degree in humans. Efficacy
f therapies may depend on the experimental model and
linical context in which they are studied, as well as the
pecific dosage, route of administration, and timing of
reatment in relation to the PCI. Treatments for MVO that
ere shown to be effective in pre-clinical research have often
ailed to translate into effective human therapies, due to
imitations of the available animal models (2). Current
nimal models lack several features, including atheroscle-
otic vascular substrate and pre-existing microvascular dys-
unction. Distal embolization models have rarely used bio-
ogically active material. Ischemia-reperfusion models have
ot included distal embolization. An ideal experimental
odel should incorporate downstream embolization of
laque constituents or thrombus into a distal coronary bed
hat has been subjected to ischemia in a hyperlipidemic or
yperglycemic animal.
Because alterations in flow (either no-reflow or slow flow)
bbreviations
nd Acronyms
CC  American College
f Cardiology
HA  American Heart
ssociation
PTP  mitochondrial
ermeability transition pore
VO  microvascular
bstruction
CI  percutaneous
oronary interventionsre dynamic by nature and may spontaneously resolve over time, the contribution of nonrandomized studies to the
urrent understanding of treatment options is limited.
lthough several randomized trials have studied different
reventive strategies, data regarding interventions for rever-
al of MVO once it exists is confined to retrospective case
eports, due to the rarity and unpredictability of this
henomenon. End points for clinical trials have been
efined at the level of the microvasculature (tissue perfu-
ion), organ (cardiac function), and clinical outcomes (sur-
ival, functional capacity). Whereas reduced tissue perfusion
ollowing PCI is associated with adverse outcomes, thera-
eutic strategies targeted at MVO must be shown to
mprove clinical end points in order to gain widespread
cceptance.
The concept of ischemic pre- and post-conditioning
efers to a variety of pharmacological and nonpharmacologi-
al cardioprotective interventions implemented before the
nset of ischemia or at the time of reperfusion. Short
pisodes of ischemia before the onset of prolonged ischemia
roduce “ischemic preconditioning.” Intermittent reperfu-
ion with repetitive episodes of recurrent ischemia is termed
ischemic post-conditioning.” Transient ischemia in remote
rgans, which prevents ischemia-reperfusion injury at a
istance, is termed “remote ischemic conditioning.” These
nterventions involve a complex and incompletely under-
tood network of molecular triggering and signaling path-
ays. Agonists that may trigger cardioprotection include
denosine, opioids, nitric oxide, bradykinin, tumor necrosis
actor-alpha, brain and atrial natriuretic peptides, and
nterleukin-6. Putative signaling pathways include open-
ng of sarcolemmal and/or mitochondrial adenosine
Figure 1. Myocardial Targets for Pharmacological Therapies to Prevent
Reperfusion No-Reflow
The inset depicts a myocardial cell and its subcellular structures involved
in cardioprotective pathways.riphosphate-dependant potassium channels and activation
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697f prosurvival kinases (Akt and ERK-1/2), protein kinase
and G, hypoxia-inducible factor-1 and endothelial
itric oxide synthase. Blockade of the mitochondrial
ermeability transition pore (MPTP) is considered a final
ommon pathway (3–6). “Pharmacological pre- and post-
onditioning” may be achieved by administration of agents
hat activate these cytoprotective pathways. Recently, ex-
natide, an antiapoptotic glucagonlike peptide-1 analogue,
hich also activates prosurvival kinases, has been shown to
educe infarct size after experimental ischemia reperfu-
ion (7).
Pharmacological agents may potentially act at more than
level to improve tissue perfusion. Platelet inhibition with
lycoprotein IIb/IIIa inhibitors may reduce downstream
mbolization and local generation of thrombus, and reduce
elease of vasoactive and chemotactic mediators from plate-
ets (8). Nitroprusside and nitroglycerin are nitric oxide
onors that vasodilate conductance vessels 200 m. Mi-
rovessels are unable to metabolize nitroglycerin to nitric
xide; in contrast, nitroprusside does not require metabo-
ism. Calcium channel blockers may attenuate microvascular
pasm and reduce myocardial ischemia and infarct size by
owering heart rate and blood pressure. Verapamil may
nhibit platelet aggregation and thrombus formation in the
icrovasculature (9) and may have a direct effect on calcium
ux across the sarcolemmal membrane or within intracellu-
ar compartments that could protect reversibly injured myo-
ytes (10). Nicardipine, a vasoselective dihydropyridine
alcium channel blocker, offers more potent and prolonged
asodilation with less risk of serious systemic side effects
han verapamil (11). Adenosine is an endogenous purine
ucleoside, which decreases arteriolar resistance and acti-
Figure 2. Mechanical Strategies to Prevent Reperfusion No-Reflow
In upper left, an angioplasty catheter is inﬂated at the site of the epicar-
dial arterial occlusion. The inset depicts aspirated thrombus.ates prosurvival kinases (12). Nicorandil is a hybrid aden- Osine triphosphate-dependant potassium channel opener
nd nitrate and may prevent reperfusion injury by blocking
he MPTP (13). The immunosuppressive agent cyclospo-
ine is also a MPTP blocker with potential cardioprotective
roperties.
yocardial Infarction Reperfusion MVO (Table 1)
asodilators. The role of vasodilators in prevention of
VO has been studied in several randomized clinical trials.
ntracoronary verapamil administered following primary
CI and followed by oral treatment improved myocardial
erfusion and regional left ventricular wall motion in treated
atients when compared to a control group (10). Intracoro-
ary adenosine and verapamil administered following pri-
ary PCI achieved equivalent improvement of myocardial
erfusion, which was superior to placebo (14). Intracoronary
dministration of nitroprusside to the distal vascular bed via
perfusion catheter before primary PCI failed to improve
oronary flow and myocardial tissue reperfusion when com-
ared to placebo, but was associated with a statistically
orderline improvement in clinical outcomes at 6 months
p  0.05) (15). In small randomized studies, intravenous
16) and distal intracoronary adenosine administration (17)
uring primary PCI achieved superior flow and ventricular
unction in comparison to a control group. The larger
MISTAD-II (Acute Myocardial Infarction Study of
denosine-II) trial (18), which compared intravenous aden-
sine to placebo, did not show a clear clinical benefit in the
reatment arm; however, a post hoc analysis suggested a
eduction in mortality and heart failure in patients treated
ithin the first 3 h after onset of evolving anterior ST-
egment elevation myocardial infarction (19). In summary,
asodilators appear to reduce MVO in the setting of infarct
CI, although the clinical significance of these findings is
nclear.
ntiplatelet therapy and thrombolysis. Antiplatelet and
hrombolytic therapy may prevent MVO. In randomized
rials of patients undergoing primary PCI, abciximab im-
roved microvascular perfusion and myocardial contractility
hen compared to placebo (20,21). In the RELAx-AMI
Randomized Early Versus Late Abciximab in Acute Myo-
ardial Infarction Treated With Primary Coronary Inter-
ention) trial (22), upstream administration of abciximab
chieved better tissue perfusion and 1-month left ventricular
unction than did treatment in the catheterization labora-
ory. A recent trial (23) showed that intracoronary versus
ntravenous administration of abciximab during primary
ngioplasty increased tissue perfusion and reduced infarct
ize. This was attributed to improved delivery of the drug to
he flow-limiting thrombus, resulting in improved dissolu-
ion of thrombi and microemboli at the ruptured plaque
nd further downstream in the microcirculation. In the
N-TIME 2 (Ongoing Tirofiban in Myocardial Infarction
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698valuation Trial), patients with acute myocardial infarction
ere randomized to receive either pre-hospital tirofiban or
lacebo before undergoing primary PCI (24). Tirofiban-
reated arteries achieved superior tissue perfusion following
ngioplasty, as evidenced by resolution of the electrocardio-
Table 1. Randomized Clinical Trials of Interventions for Prevention of MVO-
Interventions Patients, n
Vasodilators
IC Verapamil vs. placebo 40 Improved tissue
left ventricul
IV Adenosine vs. placebo 30 Improved tissue
reduced infa
IC Adenosine vs. placebo 54 Reduced angiog
IV Adenosine (low vs. high dose) vs. placebo 2,118 High-dose aden
IC Adenosine vs. verapamil vs. placebo 150 Reduced angiog
compared to
IC Nitroprusside vs. placebo 98 Similar angiogra
clinical outco
Glycoprotein IIb/IIIa inhibitors, thrombolysis, and
blockade of the complement cascade
IV Abciximab vs. placebo 2,082 Similar ST-segm
200 Reduced no-reﬂ
left ventricul
300 Reduced angiog
and clinical o
IV Abciximab vs. placebo: meta-analysis 3,266 Increased bleed
Early vs. late IV abciximab 210 Reduced angiog
IC vs. IV abciximab 154 IC abciximab re
MRI assessm
IV Tiroﬁban vs. placebo 984 Reduced no-reﬂ
IC Streptokinase vs. placebo 41 Reduced no-reﬂ
left ventricul
IV Pexelizumab vs. placebo 5,745 Similar clinical o
Cardioprotectants
IV Nicorandil vs. placebo 368 Reduced angiog
and clinical o
1,216 No reduction in
IV Cyclosporine vs. placebo 58 Reduced infarct
IC hyperoxemic reperfusion 301 Reduced infarct
Myocardial post-conditioning 30 Reduced angiog
38 Reduced infarct
Myocardial remote conditioning and morphine 96 Improved ST-se
Thrombectomy and distal embolic protection
X-sizer mechanical thrombectomy 201 Reduced angiog
Thrombus aspiration 215 Increased infarc
1,071 Reduced angiog
and clinical o
100 Reduced angiog
148 Reduced angiog
Thrombus aspiration: meta-analysis 2,417 Reduced angiog
Thrombectomy: meta-analysis 2,686 Mortality reduct
beneﬁt of th
Distal embolic protection 501 Similar ST-segm
Proximal embolic protection 284 Improved ST-se
Thrombectomy and distal embolic protection
devices: meta-analysis
6,415 Thrombus aspir
mortality, an
IC intracoronary; IV intravenous; MRImagnetic resonance imaging.raphic ST-segment elevation. A meta-analysis (25) of early prials comparing abciximab to placebo as adjunctive therapy
n acute infarct PCI showed a significant reduction in early
schemic adverse events with a trend toward reduction in
ortality. Conversely, in the CADILLAC (Controlled
bciximab and Device Investigation to Lower Late Angio-
ed Myocardial Injury and Coronary No-Reflow Following Primary Infarct PCI
End Point Effect
First Author
(Ref. #)
sion by myocardial contrast echocardiography and
tion
Taniyama et al. (10)
sion by myocardial contrast echocardiography and Micari et al. (16)
no-reﬂow and infarct size, improved clinical outcome Marzilli et al. (17)
reduced infarct size Ross et al. (18)
no-reﬂow and improved left ventricular function when
bo. Increased transient heart block with verapamil
Vijayalakshmi et al. (14)
issue perfusion and ST-segment resolution, improved Amit et al. (15)
solution and myocardial blush grade Stone et al. (26)
Doppler wire ﬂow velocity and improved
tion
Neumann et al. (20)
no-reﬂow, improved left ventricular function,
e
Montalescot et al. (21)
proved overall clinical outcome Kandzari et al. (25)
no-reﬂow, improved left ventricular function Maioli et al. (22)
infarct size and no-reﬂow by ST-segment resolution
tissue perfusion
Thiele et al. (23)
ST-segment resolution Van’t Hof et al. (24)
Doppler wire ﬂow velocity. No difference in
tion
Sezer et al. (27)
es Armstrong et al. (76)
no-reﬂow, improved ST-segment resolution
es
Ishii et al. (39)
t size Kitakaze et al. (40)
Piot et al. (43)
Stone et al. (37)
no-reﬂow and infarct size Staat et al. (41)
nd improved left ventricular function Thibault et al. (42)
resolution and reduced peak troponin I level Rentoukas et al. (44)
no-reﬂow, improved ST-segment resolution Lefevre et al. (77)
Kaltoft et al. (30)
no-reﬂow, improved ST-segment resolution
es
Vlaar et al. (32) and
Svilaas et al. (78)
no-reﬂow, improved ST-segment resolution Burzotta et al. (28)
no-reﬂow, improved ST-segment resolution Silva-Orrego et al. (31)
no-reﬂow and 30-day mortality De Luca et al. (79)
ited to manual thrombectomy devices. Synergistic
ctomy and glycoprotein IIB/IIIA inhibitors
Burzotta et al. (33)
solution, infarct size, and clinical outcomes Stone et al. (34)
resolution Haeck et al. (35)
educed mortality, mechanical thrombectomy increased
l embolic protection had a neutral effect on mortality
Bavry et al. (80)Relat
perfu
ar func
perfu
rct size
raphic
osine
raphic
place
phic t
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ent re
ow by
ar func
raphic
utcom
ing, im
raphic
duced
ent of
ow by
ow by
ar func
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raphic
utcom
infarc
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d distalasty Complications) study (26), abciximab did not im-
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699rove microvascular perfusion when compared to placebo.
his unexpected result may be due to the relatively low-risk
opulation recruited to the study and a short time interval
rom initiation of the therapy to the coronary intervention.
here is a paucity of trials that have reevaluated the current
ole of glycoprotein IIb/IIIa inhibitors in patients who
eceive adequate thienopyridine loading before acute infarct
CI. In summary, current data suggests that glycoprotein
Ib/IIIa inhibitors are especially beneficial when given
pstream in patients who have not received thienopyridine
oading.
In a small randomized trial, intracoronary thrombolysis
mmediately following primary PCI improved microvascular
ntegrity and tissue perfusion measured 2 days later by
oronary flow reserve, microvascular resistance, and TIMI
Thrombolysis In Myocardial Infarction) frame count (27).
hese findings suggest a role for in situ microvascular
hrombosis in the pathogenesis of no-reflow, although the
tudy was underpowered to study the clinical impact of this
pproach.
hrombus aspiration and embolic protection devices. Sev-
ral mechanical approaches for prevention of distal embo-
ization have been studied in the setting of primary PCI.
nitial small trials of thrombus aspiration reported conflict-
ng results (28–30). In the study by Kaltoft et al. (30),
hrombectomy did not improve ST-segment resolution and
as associated with increased infarct size. Conversely, in the
EMEDIA (Randomized Evaluation of the Effect of
echanical Reduction of Distal Embolization by
hrombus-Aspiration in Primary and Rescue Angioplasty)
28) and DEAR-MI (Dethrombosis to Enhance Acute
eperfusion in Myocardial Infarction) (31) studies, throm-
ectomy improved microvascular perfusion. In the pivotal
APAS (Thrombosis Aspiration During Percutaneous
oronary Intervention in Acute Myocardial Infarction) trial
32), thrombectomy improved tissue perfusion and reduced
ardiac death. In a pooled analysis of 11 randomized trials
hat examined the role of different thrombectomy devices in
rimary PCI, thrombectomy improved survival in patients
reated with glycoprotein IIb/IIIa inhibitors (p  0.049)
nd survival advantage was confined to manual thrombec-
omy (p  0.011) (33). Another mechanical approach for
revention of distal embolization consists of deployment of
mbolic protection devices before stenting. Distal embolic
rotection has several theoretical disadvantages when com-
ared to proximal protection, including potential trauma to
he vessel and induction of embolization as the device is
aneuvered across the lesion before deployment, lack of
rotection to side branches located proximal to the device,
nd the ability of potent vasoconstrictors to pass through
lter micropores and reach the distal microvasculature.
istal protection with a balloon occlusion and aspiration
ystem (GuardWire, Medtronic, Santa Rosa, California)
ffectively retrieved embolic debris in the EMERALD gEnhanced Myocardial Efficacy and Recovery by Aspiration
f Liberated Debris) study (34), but did not improve
icrovascular flow, decrease infarct size, or improve clinical
utcome. In the PREPARE (Proximal Embolic Protection
n Acute MI and Resolution of ST-Elevation) trial (35),
roximal embolic protection (Proxis, St. Jude Medical, St.
aul, Minnesota) improved microvascular flow as reflected
y improved immediate complete ST-segment resolution;
owever, the study was underpowered to detect clinical
enefit. No trials have directly compared these different
trategies for prevention of distal microembolization. In
ummary, current data supports routine manual thrombec-
omy during primary PCI. Distal embolic protection is of
nproven benefit and the role of proximal embolic protec-
ion, though promising, remains to be defined.
yperoxemic reperfusion. Intracoronary hyperoxemic reperfu-
ion has been advocated for prevention of reperfusion injury.
yperoxemic reperfusion improved microvascular blood
ow and decreased infarct size in a canine model of ischemia
eperfusion (36). In the AMIHOT-II (Acute Myocardial
nfarction With Hyperoxemic Therapy II) trial (37), this
pproach reduced infarct size but was not associated with
mproved tissue perfusion as assessed by ST-segment reso-
ution. In this trial, only 22% of the patients underwent
hrombectomy and 67% received glycoprotein IIb/IIIa in-
ibitors. Because the clinical benefit of hyperoxemic reper-
usion has yet to be shown, the routine use of this invasive
trategy in the current era of routine thrombectomy cannot
e recommended at present.
ytoprotection. Activation of intracellular prosurvival path-
ays has been studied in the setting of primary PCI. In 1
tudy, intravenous nicorandil started before PCI improved
yocardial perfusion and ventricular contraction (38), as
ell as long-term clinical outcome (39). However, a larger
tudy found no reduction in infarct size with nicorandil
ersus placebo (40). Myocardial post-conditioning after
irect coronary stenting by use of intermittent low-pressure
alloon inflations in the infarct-related artery reduced in-
arct size and improved microvascular perfusion as assessed
y myocardial blush (41), and long-term functional recovery
42). Pharmacological post-conditioning by intravenous ad-
inistration of cyclosporine, a direct MPTP blocker, versus
lacebo, at the time of primary PCI decreased infarct size
43). Remote post-conditioning by intermittent inflations of
blood pressure cuff on the upper limb before reperfusion
mproved ST-segment resolution following primary PCI, an
ffect that was enhanced by administration of morphine
44). These preliminary studies suggest a beneficial role for
onditioning strategies in the setting of primary infarct PCI.
owever, their efficacy in patients undergoing thrombec-
omy and receiving glycoprotein IIb/IIIa inhibitors remains
o be defined.
eversal of reperfusion no-reﬂow. Appearance of angio-
raphic no-reflow reflects the presence of severe MVO and
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700yocardial ischemia and is associated with serious adverse
linical events. Various interventions for reversal of existing
ngiographic no-reflow following primary PCI have been
eported, although no randomized trials have been per-
ormed in this setting (45). Nitroglycerin was not been
ound to be effective (46). Other reports suggested efficacy
f papaverine (47), nitroprusside (48,49), nicardipine (50),
nd abciximab (51). At present, there are no data from
andomized trials showing the clinical benefit of these
herapies.
nterventional MVO (Table 2)
mbolic protection devices. Several randomized trials have
tudied the role of embolic protection devices in the
reatment of diseased saphenous vein aortocoronary bypass
rafts. Occlusive protection devices, either distal (Guard-
ire, Medtronic) or proximal (Proxis, St. Jude Medical)
ave a theoretical advantage over distal filter catheters in
hat they capture vasoactive, proinflammatory and throm-
otic factors that might pass through filter pores and induce
icrovascular obstruction (52). However, clinical studies to
ate have not demonstrated superiority of a specific protec-
ion device. In the SAFER (Saphenous Vein Graft Angio-
lasty Free of Emboli Randomized Trial) (53), distal
mbolic protection with a balloon occlusion and aspiration
ystem (GuardWire) reduced angiographic no-reflow from
% to 3% and improved clinical outcome. In the FIRE
FilterWire Ex Randomized Evaluation) trial (54), distal
rotection with a filter-based catheter (FilterWire EX,
oston Scientific, Natick, Massachusetts) was noninferior
o the GuardWire system. In the PROXIMAL (Proximal
rotection During Saphenous Vein Graft Intervention) trial
55), the efficacy of proximal embolic protection (Proxis, St.
ude Medical) was noninferior to distal protection. In an
nalysis of the 19,546 vein graft PCI procedures in the
Table 2. Randomized Clinical Trials of Interventions for Reducing Peri-Proc
Interventions Patients, n
Glycoprotein IIb/IIIa inhibitors vs. placebo for
saphenous vein bypass grafts: pooled analysis
627
Eptiﬁbatide vs. placebo in patients undergoing
nonurgent coronary intervention
2,064
Eptiﬁbatide vs. bivalirudin in patients with
non–ST-segment elevation acute coronary syndromes
857
Nicorandil vs. verapamil in patients undergoing
rotational atherectomy
61
111
Remote ischemic pre-conditioning 242
Distal embolic protection in saphenous vein bypass grafts 801
Proximal embolic protection in saphenous vein bypass grafts 594
PCI percutaneous coronary intervention.merican College of Cardiology–National Cardiovascular eata Registry (56), use of embolic protection devices was
ndependently associated with a lower incidence of no-
eflow (odds ratio: 0.68, p  0.032), although these devices
ere only used in 22% of the cases. The underuse of this
echnology may be due to complexity of use and cost,
eflecting the need for more user-friendly and cheaper
evices.
ntiplatelet therapy and vasodilators. Although distal em-
olization is the predominant mechanism leading to MVO
nd no-reflow in interventional no-reflow, particularly dur-
ng vein graft interventions, there still may be a role for
asodilator and antiplatelet therapies to modify the flow
bnormalities. In noninfarct interventions, glycoprotein
Ib/IIIa inhibitors enhanced microvascular perfusion among
atients undergoing PCI to native coronary arteries (57),
ut did not improve clinical outcomes in patients undergo-
ng PCI to coronary bypass vein grafts (58). In a registry of
3 consecutive degenerative vein grafts undergoing stenting
ollowing intragraft administration of nicardipine (59), a
ignificant rise in serum creatine kinase levels was docu-
ented in only 4.4% of the cases and no patients sustained
Q-wave myocardial infarction. In the VAPOR (Vasodi-
ator Prevention of No-Reflow) trial (60), pre-intervention
ntragraft verapamil achieved a significant improvement in
oronary flow measured by the TIMI frame count in
atients undergoing PCI to vein grafts. Among patients
ndergoing rotational coronary atherectomy, intracoronary
icorandil reduced no-reflow when compared to verapamil
61,62).
ytoprotection. In patients undergoing elective PCI, re-
ote conditioning by transient upper-limb ischemia re-
uced myocardial injury following the procedure (63).
eversal of interventional no-reﬂow. As in the case of
eperfusion no-reflow, angiographic evidence of no-reflow in
he setting of noninfarct PCI reflects severe MVO and
l Myocardial Injury Following Noninfarct PCI
End Point Effects First Author (Ref. #)
r clinical outcomes Rofﬁ et al. (58)
ed periprocedural myocardial infarctions Blankenship et al. (81)
atide reduced angiographic no-reﬂow and
t-PCI ischemia on continuous Holter monitoring
Gibson et al. (57)
ed angiographic no-reﬂow Tsubokawa et al. (61)
ed angiographic no-reﬂow Iwasaki et al. (62)
ed periprocedural myocardial infarctions,
roved clinical outcomes
Hoole et al. (63)
ed angiographic no-reﬂow, improved clinical outcomes Baim et al. (53)
ferior to distal embolic protection Mauri et al. (55)edura
Simila
Reduc
Eptiﬁb
pos
Reduc
Reduc
Reduc
imp
Reduc
Noninxtensive myocardial ischemia. Treatment of existing inter-
v
t
v
n
o
b
R
S
p
t
i
b
s
w
d
s
c
i
H
a
c
I
c
A
t
t
(
d
d
t
r
d
A
v
h
n
c
e
m
i
H
s
o
e
o
r
w
p
t
b
a
F
a
i
S
a
M
p
s
o
c
c
o
P
i
d
M
i
f
o
P
e
t
n
t
r
i
t
w
d
p
m
r
m
M
w
d
t
R
o
S
R
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 7 , 2 0 1 0 Jaffe et al.
J U L Y 2 0 1 0 : 6 9 5 – 7 0 4 No-Reflow Systematic Approach
701entional angiographic no-reflow is confined to retrospec-
ive reports and case series. Intracoronary diltiazem (64),
erapamil (65,66), nicardipine (50,59), epinephrine (67),
itroprusside (68), adenosine (69,70), combination of aden-
sine and nitroprusside (71), and abciximab (72) have all
een reported to be efficacious.
ecommendations for Prevention of MVO
everal caveats should be considered when formulating
ractical therapy guidelines. There is a paucity of major
rials comparing different therapeutic strategies and some
nterventions are supported by only 1 positive trial. Throm-
ectomy was not performed in most trials of preventive
trategies. Most studies of glycoprotein IIb/IIIa inhibitors
ere performed before the current era of high thienopyri-
ine loading doses.
In the setting of acute ST-segment elevation infarct PCI,
hortening of the symptom-to-balloon time interval is
rucial (73). Glycoprotein IIb/IIIa inhibitors may be given
ntravenously (American College of Cardiology/American
eart Association [ACC/AHA] guideline class IIa) and
bciximab specifically may be administered via the intra-
oronary route. Upstream administration of glycoprotein
Ib/IIIa inhibitors may be considered before arrival in the
atheterization laboratory when PCI is delayed (ACC/
HA guideline class IIb) (73). It is reasonable to perform
hrombus aspiration before insertion of other devices into
he infarct-related artery (ACC/AHA guideline class IIa)
73). Although controversial (74), we believe that current
ata does not support the routine use of embolic protection
evices in native coronary arteries. Proximal embolic pro-
ection appears promising, although its clinical benefit
emains to be defined.
In the setting of noninfarct PCI, embolic protection
evices should be used for degenerated vein grafts (ACC/
HA/Society for Cardiovascular Angiography and Inter-
entions guideline class I) (75). Glycoprotein IIb/IIIa in-
ibitors should be considered when performing PCI in the
ative coronary arteries (ACC/AHA/Society for Cardiovas-
ular Angiography and Interventions guideline class I) (75),
specially in the presence of complex anatomy.
No definitive recommendations can be made for treat-
ent of no-reflow once it has occurred because proposed
nterventions have not been studied in randomized trials.
owever, based on reports from multiple nonrandomized
tudies and the paucity of alternative proven therapeutic
ptions, administration of vasodilators should be consid-
red. Our personal practice is intracoronary administration
f adenosine, verapamil, and nitroprusside in attempt to
everse MVO in this situation.
Although they may be beneficial in individual patients,
e do not currently recommend the routine use of other
harmacological and mechanical interventions such as drugshat activate survival pathways and conditioning strategies
ecause their comparative efficacy and interaction with the
bovementioned interventions has not been investigated.
or example, in trials assessing the utility of cyclosporine
nd post-conditioning, PCI was performed by direct stent-
ng without use of thrombectomy.
ummary: Future Directions
nd Unanswered Questions
icrovascular obstruction following PCI is a multifactorial
henomenon with diverse etiologies in different clinical
ettings and is associated with adverse outcome. Prevention
f MVO following elective coronary intervention is benefi-
ial in reducing cardiac injury and improving clinical out-
ome. Until recently, it was unclear whether the unfavorable
utcome associated with MVO following primary infarct
CI reflected a causal effect or whether the microcirculatory
njury was an epiphenomenon mirroring greater myocardial
amage. The TAPAS study has proven that prevention of
VO during primary PCI may reduce cardiac injury and
mprove clinical outcome. Several preventive measures ef-
ectively decrease the degree of MVO and improve clinical
utcome in the setting of both acute infarct and elective
CI. Unfortunately, there is limited data comparing the
fficacy of different strategies. There is no randomized data
o guide selection of therapies for reversal of existing
o-reflow.
The goal of the various pharmacological and mechanical
herapeutic strategies that are targeted at prevention and
eversal of MVO and no-reflow is to minimize cardiac
njury. Specific interventions targeted at reperfusion injury
hat activate intracellular cardioprotective signaling path-
ays have been shown to improve tissue perfusion and
ecrease myocardial injury following PCI. These ap-
roaches hold great promise for achievement of further
yocardial preservation. Ultimately, strategies designed to
educe MVO and to activate intracellular cardioprotective
echanisms converge at the tissue level. Reduction of
VO is cardioprotective and cardioprotection is associated
ith improved tissue perfusion. Future research should be
irected at refining these techniques and implementing
hem for reversal of no-reflow once it has occurred.
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